Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2021 16:01 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“Algernon” or the “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical...
November 19, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
November 17, 2021 16:14 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces Share Consolidation

VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“Algernon” or “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical...
November 01, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

VANCOUVER, British Columbia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
October 21, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market

VANCOUVER, British Columbia, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
October 13, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
October 08, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study

VANCOUVER, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
September 22, 2021 07:30 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
September 22, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors

VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...
September 20, 2021 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right